The risk of adverse outcomes in association with use of testosterone products: A cohort study using the UK-based general practice research database

British Journal of Clinical Pharmacology

Volumn 75, Issue 1, 2013, Pages 260-270

  Jick, Susan S ^a   Hagberg, Katrina Wilcox ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Rate; Relative risk; Testosterone

Indexed keywords

TESTOSTERONE UNDECANOATE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; COHORT ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; GENERAL PRACTICE; HUMAN; HYPERTENSION; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATISM; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYCYTHEMIA; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATISM; RISK; TESTOSTERONE;

EID: 84871157924     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04326.x     Document Type: Article

References (12)

1. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-48.
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
3. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899-901.
4. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 2000; 110: 237-8.
5. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7.
6. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek RE, Krasnoff K, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
7. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proc 2007; 82: 29-39.
8. Fernandez-Balsells MM, Hassan M, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Adverse effects of testosterona therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
9. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14: 2257-60.
10. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
11. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-9.
12. Jick SS, Kaye JA, Vasilakis-Scaramozza C, García Rodríguez LA, Ruigómez A, Meier DR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.